<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pentamidine (oral inhalation): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pentamidine (oral inhalation): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pentamidine (oral inhalation): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="104534" href="/d/html/104534.html" rel="external">see "Pentamidine (oral inhalation): Drug information"</a> and <a class="drug drug_patient" data-topicid="104537" href="/d/html/104537.html" rel="external">see "Pentamidine (oral inhalation): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F44486476"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nebupent</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F45043322"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Miscellaneous</span>;</li>
<li>
<span class="list-set-name">Antifungal Agent</span>;</li>
<li>
<span class="list-set-name">Antiprotozoal</span></li></ul></div>
<div class="block dop drugH1Div" id="F44486525"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd779d2b-f03a-4872-ad1b-201fdabd029f">
<i>Pneumocystis jirovecii</i> pneumonia; primary or secondary prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Pneumocystis jirovecii</b></i>
<b> pneumonia; primary or secondary prophylaxis (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;5 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Hematopoietic stem cell transplantation recipients: Inhalation: 9 mg/kg (maximum dose: 300 mg/dose) once monthly (every 4 weeks) via Respirgard II nebulizer (Tomblyn 2009).</p>
<p style="text-indent:-2em;margin-left:6em;">Leukemia patients (Weinthal 1994): Inhalation:</p>
<p style="text-indent:-2em;margin-left:8em;">Children &lt;4 years: 150 mg/dose once monthly (every 4 weeks) via Respirgard II nebulizer.</p>
<p style="text-indent:-2em;margin-left:8em;">Children 4 to 5 years: 300 mg/dose once monthly (every 4 weeks) via Respirgard II nebulizer.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents: Inhalation: 300 mg once monthly (every 4 weeks) via Respirgard II nebulizer (HHS [OI adult 2020]; HHS [OI pediatric 2019]; <i>Red Book</i> [AAP 2018]; Quinn 2017; Tomblyn 2009).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51152556"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51152557"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F44486526"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="104534" href="/d/html/104534.html" rel="external">see "Pentamidine (oral inhalation): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d62b403-f354-49e6-af60-bf440a7b97f7">
<i>Pneumocystis</i> pneumonia, prophylaxis, primary and secondary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>
<i>Pneumocystis </i>pneumonia, prophylaxis, primary and secondary (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Patients with HIV: <b>Inhalation: </b>300 mg once every 4 weeks via Respirgard II nebulizer. Continue prophylaxis following initiation of antiretroviral therapy (ART) until CD4 count &gt;200 cells/mm<sup>3</sup> for &gt;3 months; some experts discontinue prophylaxis in patients with a CD4 count between 100 to 200 cells/mm<sup>3</sup> who are receiving ART and have had an undetectable viral load for ≥3 to 6 months (HHS [OI adult 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">Immunocompromised host, HIV-uninfected (eg, solid organ transplant recipients, cancer related, hematopoietic cell transplant) (off-label use): <b>Inhalation: </b>300 mg once every 3 or 4 weeks via Respirgard II nebulizer (ASBMT/IDSA [Tomblyn 2009]; AST-IDCOP [Fishman 2019]).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990688"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied). Use with caution.</p></div>
<div class="block doha drugH1Div" id="F50987990"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied). Use with caution.</p></div>
<div class="block adr drugH1Div" id="F44486498"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;5%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (66%), dizziness (45%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (1% to 63%), dyspnea (48%), wheezing (32%), bronchospasm (≤15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (51%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 5%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Night sweats</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, dysgeusia, nausea, oral candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes virus infection, herpes zoster, influenza</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (≤5%), bronchitis, sinusitis, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Night sweats</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abscess (oral), abdominal cramps, abdominal pain, acute pancreatitis, acute rhinitis, ageusia, amnesia, anaphylaxis, anxiety, arthralgia, asthma, bacterial pneumonia, blepharitis, blurred vision, body odor, bronchitis, cerebrovascular accident, chest congestion, chest tightness, colitis, confusion, conjunctivitis, constipation, contact lens intolerance, cyanosis, cytomegalovirus disease (including colitis and retinitis), cytopenia, depression, dermatitis, desquamation, diabetes mellitus, disruption of body temperature regulation, drowsiness, dry hair, dyspepsia, dyspnea, emotional lability, encephalitis (viral), eosinophilia, eosinophilic pneumonitis, erythema, esophageal candidiasis, esophagitis, eye pain, facial edema, flank pain, gag reflex, gastritis, gastric ulcer, gingivitis, gout, hallucination, hematochezia, hemianopia, hemoptysis, hepatic insufficiency, hepatitis, hepatomegaly, herpes virus infection (pharyngeal), hiatal hernia, histoplasmosis, hyperglycemia, hyperkalemia, hypersensitivity reaction, hypertension, hyperventilation, hypocalcemia, hypoesthesia, hypoglycemia, hypotension, hypothermia, hypoxia, increased blood urea nitrogen, increased bronchial secretions, increased serum creatinine, infection (mycoplasma), insomnia, interstitial pneumonitis, Kaposi's sarcoma, laryngitis, laryngospasm, lethargy, lower extremity edema, melena, meningitis (cryptococcal infection), myalgia, nasal congestion, nephritis, nervousness, neuralgia, neuropathy, neutropenia, oral herpes, oral mucosa ulcer, otitis, palpitations, pancreatitis, pancytopenia, paranoia, paresthesia, peripheral neuropathy, pleurisy, pneumothorax, pruritus, pulmonary disease, rales, renal failure, renal insufficiency, renal pain, rhinitis, seizure, sepsis (central venous line-related), serious infection (extrapulmonary pneumocystosis), SIADH, sialorrhea, skin rash, splenomegaly, Stevens-Johnson syndrome, ST segment changes on ECG, syncope, tachycardia, tachypnea, thrombocytopenia, tonsillitis, torsades de pointes, tremor, tuberculosis, unsteady gait, urinary incontinence, urticaria, vasodilation, vasculitis, ventricular tachycardia, vertigo, vomiting, xeroderma, xerostomia</p></div>
<div class="block coi drugH1Div" id="F44486495"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to pentamidine isethionate or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F44486496"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Use inhalation formulation with caution in patients with asthma. May induce bronchospasm or cough, especially in patients with a smoking or asthma history (an inhaled bronchodilator prior to pentamidine may ameliorate symptoms).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: Use with caution in patients with a history of pancreatic disease or elevated amylase/lipase levels; acute pancreatitis (with fatality) has been reported. Discontinue inhalational pentamidine if signs/symptoms of acute pancreatitis occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• PCP: Acute PCP may develop despite aerosolized pentamidine prophylaxis. Although rare, extrapulmonary PCP disease may occur and has been associated with aerosolized pentamidine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adverse effects: According to the manufacturer, extent and consequence of pentamidine accumulation following chronic inhalation therapy are not known. Patients receiving pentamidine inhalation should be closely monitored for the development of serious adverse reactions that have occurred with parenteral administration of pentamidine, including hypotension, hypoglycemia, hyperglycemia, hypocalcemia, anemia, thrombocytopenia, leukopenia, hepatic or renal dysfunction, ventricular tachycardia (eg, torsade de pointes), pancreatitis, Stevens-Johnson syndrome, hyperkalemia and abnormal ST segment of ECG.</p></div>
<div class="block foc drugH1Div" id="F44486544"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Inhalation, as isethionate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nebupent: 300 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F44486479"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F44486546"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Nebupent Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $200.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Pentamidine Isethionate Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $112.50 - $180.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614617"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral inhalation: Deliver via Respirgard II nebulizer with appropriately sized face mask until nebulizer is emptied (up to 30 to 45 minutes). Use appropriate precautions to minimize exposure to health care personnel; refer to individual institutional policy. An inhaled bronchodilator may be administered prior to each dose if the patient experiences bronchospasm or cough with administration; do not use Respirgard to administer albuterol. Do not mix with other nebulizer solutions.</p></div>
<div class="block adm drugH1Div" id="F44486530"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Inhalation:</b> Deliver via Respirgard II nebulizer until nebulizer is emptied (~30 to 45 minutes). Administer at a flow rate of 5 to 7 L/minute from a 40 to 50 pound-per-square inch (PSI) oxygen or air source. A 40 to 50 PSI air compressor can be used alternatively, with a set flow rate at 5 to 7 L/minute or a set pressure of 22 to 25 PSI. Air compressors &lt;20 PSI should not be used. Use appropriate precautions to minimize exposure to healthcare personnel; refer to individual institutional policy.</p></div>
<div class="block sts drugH1Div" id="F44486509"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 20°C to 25°C (68°F to 77°F); protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends the use of freshly prepared solutions for inhalation; however, may be stored for up to 48 hours in the vial at room temperature if protected from light. </p></div>
<div class="block usep drugH1Div" id="F53571288"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prevention of pneumonia caused by <i>Pneumocystis jirovecii </i>in high-risk patients with HIV (FDA approved in ages ≥17 years and adults).</p></div>
<div class="block cyt drugH1Div" id="F44486505"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F44486502"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F44486491"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">It is not known if clinically significant concentrations reach the fetus when administered via the aerosolized route. Information related to fetal outcomes following maternal use of pentamidine is limited. If administered via the aerosolized route, maternal serum concentrations are lower, minimizing the exposure to the fetus (Gates 1993; Nanda 1992; Sperling 1992). Concern regarding occupational exposure and theoretical risk to pregnant health care workers has been discussed in the literature. Pregnant health care workers should avoid aerosolized exposure if possible (Conover 1988; Ito 1994; Smaldone 1991).</p>
<p style="text-indent:0em;margin-top:2em;">Aerosolized pentamidine may be used as an alternative agent for the prophylaxis of <i>Pneumocystis</i> pneumonia (PCP) in pregnant females with HIV infection who either cannot tolerate the preferred therapy or who wish to avoid it during the first trimester of pregnancy (HHS [OI adult 2020]).</p></div>
<div class="block mopp drugH1Div" id="F53571289"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Bronchospasm, cough, wheezing with administration; liver function tests, renal function tests, blood glucose, serum potassium and calcium, CBC with differential and platelet count, blood pressure.</p></div>
<div class="block pha drugH1Div" id="F44486513"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Interferes with microbial RNA/DNA, phospholipids and protein synthesis, through inhibition of oxidative phosphorylation and/or interference with incorporation of nucleotides and nucleic acids into RNA and DNA</p></div>
<div class="block phk drugH1Div" id="F44486515"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Inhalation: Limited systemic absorption with chronic therapy, potential accumulation and systemic effects unknown</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Binds to tissues and plasma protein; high concentrations are found in the liver, kidney, adrenals, spleen, lungs, and pancreas; poor penetration into CNS; following oral inhalation, high concentrations are found in bronchoalveolar fluid</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: IV: 5 to 8 hours; IM: 7 to 11 hours; may be prolonged with severe renal impairment </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F45524663"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Nebupent</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Pentacarinat</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Pentacarinat</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Pentacarinat</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Pneumopent</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Pentacarinat</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Nebupent</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Pentacarinat</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Nebupent</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention. <i>Pneumocystis jiroveci</i> (formerly <i>carinii</i>) Pneumonia (PCP). <a href="https://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Pneumocystis_jiroveci.pdf" target="_blank">http://www.dpd.cdc.gov/dpdx/HTML/PDF_Files/MedLetter/Pneumocystis_jiroveci.pdf</a>. Accessed September 15, 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1424505">
<a name="1424505"></a>Comtois R, Pouliot J, Gervais S, et al. High Pentamidine Levels Associated With Hypoglycemia and Azotemia in a Patient With <i>Pneumocystis carinii</i> Pneumonia. <i>Diagn Microbiol Infect Dis.</i> 1992;15(6):523-526.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/1424505/pubmed" id="1424505" target="_blank">1424505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3190049">
<a name="3190049"></a>Conover B, Goldsmith JC, Buehler BA, et al. Aerosolized Pentamidine and Pregnancy. <i>Ann Intern Med.</i> 1988;109(11):927.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/3190049/pubmed" id="3190049" target="_blank">3190049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31077616">
<a name="31077616"></a>Fishman JA, Gans H; AST Infectious Diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13587. doi:10.1111/ctr.13587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/31077616/pubmed" id="31077616" target="_blank">31077616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2929699">
<a name="2929699"></a>Fortunato SJ and Bawdon RE. Determination of Pentamidine Transfer in the <i>in vitro</i> Perfused Human Cotyledon With High-Performance Liquid Chromatography. <i>Am J Obstet Gynecol.</i> 1989;160(3):759-761.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/2929699/pubmed" id="2929699" target="_blank">2929699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8331631">
<a name="8331631"></a>Gates HS Jr, Barker CD. <i>Pneumocystis carinii</i> Pneumonia in Pregnancy. A Case Report. <i>J Reprod Med.</i> 1993;38(6):483-486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/8331631/pubmed" id="8331631" target="_blank">8331631</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Goa KL and Campoli-Richards DM. Pentamidine Isethionate. A Review of Its Antiprotozoal Activity, Pharmacokinetic Properties and Therapeutic Use in <i>Pneumocystis carinii</i> Pneumonia. <i>Drugs.</i> 1987;33(3):242-258.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8190532">
<a name="8190532"></a>Hand IL, Wiznia AA, Porricolo M, et al. Aerosolized Pentamidine for Prophylaxis of <i>Pneumocystis carinii</i> Pneumonia in Infants With Human Immunodeficiency Virus Infection. <i>Pediatr Infect Dis J. </i>1994;13(2):100-104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/8190532/pubmed" id="8190532" target="_blank">8190532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2067889">
<a name="2067889"></a>Hughes WT. <i>Pneumocystis carinii</i> Pneumonia: New Approaches to Diagnosis, Treatment, and Prevention. <i>Pediatr Infect Dis J.</i> 1991;10(5):391-399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/2067889/pubmed" id="2067889" target="_blank">2067889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7956402">
<a name="7956402"></a>Ito S, Koren G. Estimation of Fetal Risk From Aerosolized Pentamidine in Pregnant Healthcare Workers. <i>Chest.</i> 1994;106(5):1460-1462.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/7956402/pubmed" id="7956402" target="_blank">7956402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1448123">
<a name="1448123"></a>Masur H. Prevention and Treatment of <i>Pneumocystis</i> Pneumonia. <i>N Engl J Med.</i> 1992;327(26):1853-1860.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/1448123/pubmed" id="1448123" target="_blank">1448123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2191850">
<a name="2191850"></a>Monk JP, Benfield P. Inhaled Pentamidine. An Overview of Its Pharmacological Properties and a Review of Its Therapeutic Use in <i>Pneumocystis carinii</i> Pneumonia. <i>Drugs.</i> 1990;39(5):741-756.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/2191850/pubmed" id="2191850" target="_blank">2191850</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nanda D, Tannenbaum I, Landesman S, et al. Pentamidine Prophylaxis in Pregnancy. <i>Am J Obstet Gynecol. </i>1992;166:387.</div>
</li>
<li>
<div class="reference">
                  NebuPent (pentamidine isethionate) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; October 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8530781">
<a name="8530781"></a>Pelucio MT, Rothenhaus T, Smith M, et al. Fatal Pancreatitis as a Complication of Therapy for HIV Infection. <i>J Emerg Med.</i> 1995;13(5):633-637.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/8530781/pubmed" id="8530781" target="_blank">8530781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29866879">
<a name="29866879"></a>Quinn M, Fannin JT, Sciasci J, et al. Pentamidine for prophylaxis against Pneumocystis jirovecii pneumonia in pediatric oncology patients receiving immunosuppressive chemotherapy. <i>Antimicrob Agents Chemother</i>. 2018;62(8):e00173-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/29866879/pubmed" id="29866879" target="_blank">29866879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7548518">
<a name="7548518"></a>Schwebke K, Fletcher CV, Acosta EP, et al. Pentamidine Concentrations in a Mother With AIDS and in Her Neonate. <i>Clin Infect Dis.</i> 1995;20(6):1569-1570.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/7548518/pubmed" id="7548518" target="_blank">7548518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7744406">
<a name="7744406"></a>Singh G, el-Gadi SM, Sparks RA. Pancreatitis Associated With Aerosolized Pentamidine. <i>Genitourin Med. </i>1995;71(2):130-131.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/7744406/pubmed" id="7744406" target="_blank">7744406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1875979">
<a name="1875979"></a>Smaldone GC, Vinciguerra C, Marchese J. Detection of Inhaled Pentamidine in Health Care Workers. <i>N Engl J Med.</i> 1991;325(12):891-892.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/1875979/pubmed" id="1875979" target="_blank">1875979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1542322">
<a name="1542322"></a>Sperling RS, Stratton P, O'Sullivan MJ, et al. A Survey of Zidovudine Use in Pregnant Women With Human Immunodeficiency Virus Infection. <i>N Engl J Med.</i> 1992;326(13):857-861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/1542322/pubmed" id="1542322" target="_blank">1542322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al. Guidelines for Preventing Infectious Complications Among Hematopoietic Cell Transplantation Recipients: A Global Perspective. <i>Biol Blood Marrow Transplant.</i> 2009;15(10):1143-1238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. <a href="https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf" target="_blank">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Updated December 24, 2019. Accessed January 2, 2020.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8270969">
<a name="8270969"></a>Weinthal J, Frost JD, Briones G, Cairo MS. Successful Pneumocystis carinii pneumonia prophylaxis using aerosolized pentamidine in children with acute leukemia. <i>J Clin Oncol</i>. 1994;12(1):136-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentamidine-oral-inhalation-pediatric-drug-information/abstract-text/8270969/pubmed" id="8270969" target="_blank">8270969</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 104535 Version 85.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
